Oruka Therapeutics, Inc. - 10-Q Filing

Oruka Therapeutics reports Q3 2026 financial results with significant changes to Series B preferred stock weighted-average share counts.

SEC EDGAR ·

Tickers: $ORKA

Read the full article at SEC EDGAR

More Regulatory news